Todas las vacunas actuales llevan parte del coronavirus.
The Oxford–AstraZeneca COVID-19 vaccine is a replication-deficient simian adenovirus vector, containing the full‐length codon‐optimised coding sequence of SARS-CoV-2 spike protein along with a tissue plasminogen activator (tPA) leader sequence.
The BioNTech technology for the BNT162b2 vaccine is based on use of nucleoside-modified mRNA (modRNA) which encodes a mutated form of the full-length spike protein found on the surface of the SARS-CoV-2 virus, triggering an immune response against infection by the virus protein.
The active ingredient is an mRNA sequence containing a total of 4101 nucleotides that encodes the full-length SARS-CoV-2 spike (S) glycoprotein, with two mutations (K986P and V987P) designed to stabilize the pre-fusion conformation.
BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products
CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech
Covaxin (codenamed as BBV152) is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.
CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre
The mechanism of production of this vaccine is based on the inactivated vaccine. In other words, "it is made of a coronavirus that has been weakened or killed by chemicals, similar to how polio immunizations are made."
WIBP-CorV is one of two inactivated virus COVID-19 vaccines developed by Sinopharm.
Gam-COVID-Vac is a viral vector vaccine based on two recombinant replication-defective human adenoviruses: Ad26 (serotype 26) and Ad5 (serotype 5). The viruses contain the gene that encodes the full-length spike protein (S) of SARS-CoV-2 to stimulate an immune response. Each dose contains (1.0 ± 0.5) × 1011 particles of gene. Both Ad26 and Ad5 were modified to remove the E1 gene to prevent replication.
The vaccine is based on technology similar to the Sputnik V COVID-19 vaccine and the Oxford–AstraZeneca COVID-19 vaccine. It consists of a replication-incompetent recombinant adenovirus type 26 (Ad26) vector expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in a stabilized conformation.
FINLAY-FR-2 is a conjugate vaccine. It consists of the receptor binding domain of the SARS-CoV-2 spike protein conjugated chemically to tetanus toxoid.